Article
Brochure
Executive Resource
Insight Hub
Video
Ext. Publication
Home /
Insights & Resources
Insights & Resources
Start exploring insights from across the industries we serve, featuring the latest industry trends, compliance alerts, tax and accounting news and much more.
- Alternative Investments
- Banking
- Blockchain & Digital Assets
- Construction
- Consumer Products
- Energy Transition
- Financial Services
- Food & Beverage
- General Business
- Government
- Health Care
- Higher Education
- Hospitality & Entertainment
- Industrial Products
- Insurance
- Life Sciences
- Not-for-Profit
- Oil & Gas
- Oilfield Services
- Real Estate
- Renewable Fuels
- Technology
- Transportation & Logistics
- Accounting Advisory
- Artificial Intelligence
- Asset Management Consulting
- Asset Tracing
- Cybersecurity
- Data Privacy
- Digital Transformation
- Energy Compliance
- Executive & Leadership Coaching
- Family Law
- Forensics & Litigation
- Government Consulting
- Health Care Valuation
- IT Advisory
- Risk Advisory
- Sustainability Consulting
- Transaction Advisory
- Trust & Estate
- Valuation
Explore Q3 2025 trends in Texas life sciences, from Series B collapse and pipeline bottlenecks to sector divergence and record late-stage capital.
Explore Weaver’s 2025 Corporate Responsibility Report, featuring our first double materiality assessment and updates on our sustainability progress.
Executive ResourceLearn how boards can identify compliance blind spots, strengthen governance and manage regulatory risk amid constant change.
Learn when to rebuild or rightsize your SOX or internal audit program. Our Second Line Ready series helps you move forward with clarity and purpose.
SOX programs often stall from slow drift and misaligned execution. Weaver’s Second Line Ready series offers a clear path to getting back on track.
Life sciences companies often overlook SOX in IPO prep. Discover how early action and targeted strategies can strengthen investor confidence.
Weaver’s professionals discuss tax legislation and economic trends. Tips for audit and SOX compliance, M&A accounting as well as system implementations.
Board members might consider how recent government activity, climate considerations and supply chain vulnerabilities will affect their businesses.
J.P. Morgan’s Q3 2024 Biopharma Report highlights robust venture investments, shifting licensing trends and a resurgence in IPO activity.
The Q3 2024 Medtech Report from J.P. Morgan spotlights heightened investments, mergers and public offerings, signaling a positive industry outlook.
Boards and management may want to consider how recent Fed activity, election uncertainty, and emerging ERP considerations will affect their businesses.
Download Weaver's ESG Report to learn about our commitment to operating openly, ethically and transparently as a firm that is focused on the future.
